Abstract
Bisphosphonates have been implicated in the induction of medication-related osteonecrosis of the jaw (MRONJ) since 2004. Since then, the spectrum of drugs implicated in the onset of MRONJ has broadened to include other antiresorptive and antiangiogenic drugs. Denosumab is an antiresorptive drug that has been on the market since 2010. Denosumab inhibits osteoclast formation, function, and survival and increases bone mineral density. As a result, denosumab is indicated for the treatment of osteoporosis and bone metastases. This article reports 2 cases of MRONJ associated with denosumab use. The characteristics and progression of MRONJ in patients who take denosumab are reviewed, and therapeutic measures are discussed.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 42-46 |
| Number of pages | 5 |
| Journal | General dentistry |
| Volume | 67 |
| Issue number | 1 |
| State | Published - Jan 1 2019 |
Fingerprint
All Science Journal Classification (ASJC) codes
- Dentistry(all)
Cite this
Denosumab-related osteonecrosis of the jaw : a report of 2 cases and review of the literature. / Chehal, Hardeep; Nikitakis, Nikolaos G.; Islam, Mohammed N.; Goodchild, Jason H.; Mordini, Lorenzo; Bhattacharyya, Indraneel.
In: General dentistry, Vol. 67, No. 1, 01.01.2019, p. 42-46.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Denosumab-related osteonecrosis of the jaw
T2 - a report of 2 cases and review of the literature
AU - Chehal, Hardeep
AU - Nikitakis, Nikolaos G.
AU - Islam, Mohammed N.
AU - Goodchild, Jason H.
AU - Mordini, Lorenzo
AU - Bhattacharyya, Indraneel
PY - 2019/1/1
Y1 - 2019/1/1
N2 - Bisphosphonates have been implicated in the induction of medication-related osteonecrosis of the jaw (MRONJ) since 2004. Since then, the spectrum of drugs implicated in the onset of MRONJ has broadened to include other antiresorptive and antiangiogenic drugs. Denosumab is an antiresorptive drug that has been on the market since 2010. Denosumab inhibits osteoclast formation, function, and survival and increases bone mineral density. As a result, denosumab is indicated for the treatment of osteoporosis and bone metastases. This article reports 2 cases of MRONJ associated with denosumab use. The characteristics and progression of MRONJ in patients who take denosumab are reviewed, and therapeutic measures are discussed.
AB - Bisphosphonates have been implicated in the induction of medication-related osteonecrosis of the jaw (MRONJ) since 2004. Since then, the spectrum of drugs implicated in the onset of MRONJ has broadened to include other antiresorptive and antiangiogenic drugs. Denosumab is an antiresorptive drug that has been on the market since 2010. Denosumab inhibits osteoclast formation, function, and survival and increases bone mineral density. As a result, denosumab is indicated for the treatment of osteoporosis and bone metastases. This article reports 2 cases of MRONJ associated with denosumab use. The characteristics and progression of MRONJ in patients who take denosumab are reviewed, and therapeutic measures are discussed.
UR - http://www.scopus.com/inward/record.url?scp=85060032344&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85060032344&partnerID=8YFLogxK
M3 - Article
C2 - 30644830
AN - SCOPUS:85060032344
VL - 67
SP - 42
EP - 46
JO - General Dentistry
JF - General Dentistry
SN - 0363-6771
IS - 1
ER -